用炎症酶抑制剂功能化的生物材料-前提和前景
Norina Vinţeler1, Claudia Nicoleta Feurdean1, Regina Petkes2
1Department of Oral Rehabilitation, Faculty of Dentistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Journal of functional biomaterials
|February 23, 2024
概括
炎症酶驱动口腔疾病,如牙周炎和一般炎症状况. 使用植物化学品和药品的新型疗法提供了有希望的策略来抑制炎症体通路并管理这些病理.
科学领域:
- 免疫学 免疫学 免疫学
- 口腔病理学 口腔病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症体是天生的免疫系统的关键组成部分,通过酶激活和细胞因子释放调解炎症反应.
- 失调的炎酶激活与各种疾病有关,包括牙周炎,自身免疫性疾病和自身炎症性疾病.
- 了解炎症体通路对于开发有针对性的治疗干预措施至关重要.
研究的目的:
- 审查有关炎症因子参与口腔和全身疾病的文献.
- 探索治疗策略,以控制炎症酶介导的发病.
- 确定治疗炎症相关疾病的新方法,特别是在口腔病理学中.
主要方法:
- 在文献中搜索有关炎症酶在疾病发病和治疗中的研究.
- 对正规和非正规的炎症酶激活途径的分析.
- 对药物和植物化学剂的审查,这些药物和植物化学剂针对炎症组分和信号.
主要成果:
- 炎症酶在牙周炎和其他炎症性疾病的发病过程中发挥着重要作用.
- 药品可以通过向信号通路,组件或下游细胞因子来抑制炎症体.
- 植物化学物质通过中和参与炎症酶激活的活性氧物种来证明其潜力.
- 纳米材料上的功能化生物材料为多式口腔疾病治疗提供了未来的方向.
结论:
- 炎症酶抑制是口腔和全身炎症疾病的可行治疗策略.
- 植物化学品和制药剂为控制炎症体活动提供了多种机制.
- 基于生物材料的先进方法对未来的口腔病理治疗有希望.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


